Sialylated glycoproteins
AssigneeMomenta Pharmaceuticals, Inc.
InventorsBirgit C. SCHULTES, Chia Lin CHU, Laura RUTITZKY, Lynn ZHANG, Leona E. LING
Life of this patent
Estimating the term…
Abstract
Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.
Claims22
A pharmaceutical preparation formulated for subcutaneous administration, said preparation comprising polypeptides comprising an Fc region, wherein at least 50% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages.
A pharmaceutical preparation comprising polypeptides having an Fc region, wherein at least 50% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages and less than 50% of branched glycans on the Fc region are mono-sialylated on the α 1,3 arm by way of a NeuAc-α 2,6-Gal terminal linkage.
A pharmaceutical preparation comprising polypeptides having an Fc region, wherein at least 50% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages and less than 50% of branched glycans on the Fc region are mono-sialylated on the α 1,6 arm by way of a NeuAc-α 2,6-Gal terminal linkage.
A pharmaceutical preparation comprising polypeptides having an Fc region, wherein at least 85% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages.
A method of increasing reticulated platelets or producing new platelets in a subject in need thereof, comprising administering to the subject a pharmaceutical preparation comprising polypeptides comprising an Fc region, wherein at least 85% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages.
Dependencies are inferred from the claim text.